| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 92.10 | 10.8% | 28.7% |
| Total Income | 92.10 | 10.8% | 28.7% |
| Expenditure | 86.93 | 15.6% | 29.6% |
| PBT | — | ||
| Net Profit | -31.10 | 1494.6% | 1511.4% |
| OPM | 5.62% | 3.91pp | 0.65pp |
| NPM | -33.77% | 36.46pp | 31.07pp |
| EPS | -0.18 | 1900.0% | 1700.0% |
Xeris Biopharma Reports Q2 2026 Financial Results
06 Aug 2026 · 6 Aug, 4:55 pm
Summary
Xeris Biopharma reported strong second quarter 2026 results, with total revenue increasing 29% year-over-year to $92.1 million, primarily driven by a 34% rise in net product revenue to $91.0 million. Recorlev was a key growth driver, with net revenue up 81% year-over-year. Gross margin improved to 86%, and Adjusted EBITDA increased to $19.3 million. The company tightened its full-year 2026 revenue guidance to $385 million to $390 million, reflecting confidence in its portfolio and business trajectory.
Key Highlights
- 1
Total revenue increased by 29% year-over-year to $92.1 million for the second quarter of 2026.
- 2
Net product revenue grew 34% year-over-year to $91.0 million in Q2 2026, driven by Recorlev.
- 3
Recorlev net revenue saw an 81% year-over-year increase, reaching approximately $57 million in the second quarter.
- 4
Gross margin improved to 86% in the second quarter of 2026, up from 82% in the same period last year.
- 5
Adjusted EBITDA for the second quarter of 2026 was $19.3 million, an improvement of $6.7 million compared to the prior year.
- 6
The company tightened its full-year 2026 total revenue guidance to $385 million to $390 million.
Management Comments
John Shannon
The second quarter was another strong period for Xeris, with net product revenue growing 34% year-over-year, driven by Recorlev’s exceptional commercial momentum. The strategic investments we made for Recorlev earlier this year are gaining traction, and we expect their contribution to become increasingly meaningful as we move through the second half of 2026. Additionally, Gvoke delivered solid sequential improvement in line with our expectations, and Keveyis continued to provide a consistent, high-value contribution to our business. Beyond our commercial execution, the second quarter also brought an important strategic milestone. We received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new Keveyis patent expected to extend intellectual property protection through at least 2039, reinforcing our long-term commitment to the primary periodic paralysis community. With a strong first half behind us, we are tightening our full-year guidance to $385–$390 million, reflecting our confidence in the team, the portfolio, and the trajectory of our business.
Informational and educational content only. Not investment advice.